As BioNTech predicts a drop in its mother lode of Covid sales, execs hint at coming M&A deals
BioNTech’s Covid-19 vaccine took center stage at the company’s Q1 call with investors on Monday — and though execs saw sales triple last quarter, they’re also thinking about what comes next as the pandemic’s course remains uncertain.
That leaves the door open for some potential M&A action, according to CFO Jens Holstein, though he declined to get into the details.
“The main focus of our investments remains to invest in our research and development activities,” Holstein said on the call. “We have of course looked, and continuously look, into additions in terms of transactions that we can make, collaborations, all kinds of things … but we can’t give you closer guidance on where and when we will invest.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.